Abstract:Infection is the most dramatic complication in patients with knee megaprosthesis. Its management is more complex in comparison with patients with primary arthroplasty, with a high risk of relapse. Lytic bacteriophages are considered to have a high potential in patients with prosthetic joint infection as it has been demonstrated that they have a synergistic anti-biofilm activity with antibiotics. The Defensive Antibacterial Coating (DAC®) hydrogel is a hydrogel available in the market that has been designed to prevent the adherence of bacteria on a prosthetic joint and to have the ability to transport and release anti-bacterial substances such as antibiotics. We report here the case of a patient with a catastrophic relapsing Staphylococcus aureus knee megaprosthesis infection without prosthesis loosening. We firstly perform phage susceptibility testing of the patient's strain to select an active cocktail, under the supervision of the French health authority. Then, we performed, as salvage therapy, a debridement and implant retention procedure with application of a selected cocktail of bacteriophages that was prepared extemporaneously within the DAC® hydrogel. A free flap for soft tissue coverage was required and empirical antibiotic treatment was started immediately after the surgery. Unfortunately, at 5 days after the surgery, while the local aspect of the surgical site was favorable, the patient developed myocardial infarction which required emergency stenting and dual antiplatelet therapy that were rapidly associated with bleeding at the surgical site, leading to a new prosthesis exposition. As a consequence, a transfemoral amputation was finally performed several months later. We also evaluated in vitro the impact of DAC® hydrogel on bacteriophage activity and showed that the selected phages were released very rapidly from the DAC® hydrogel, and then their titers were stable for at least 6 h. This case demonstrated the feasibility of the use of bacteriophages within a hydrogel to treat patients for knee megaprosthesis infection during a debridement procedure. The implementation requires identification of the pathogen before the debridement in order to perform phage susceptibility testing of the patient's strain and to identify a hospital pharmacist who will accept to do the preparation and to take the responsibility of the magistral preparation.

Bacteriophage-Delivering Hydrogels: Current Progress in Combating Antibiotic Resistant Bacterial Infection

Insights into the Preparation of and Evaluation of the Bactericidal Effects of Phage-Based Hydrogels

Phage-Based antibacterial hydrogels for bacterial targeting and Ablation: Progress and perspective

Phage therapy: A targeted approach to overcoming antibiotic resistance

Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review

Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens

Phage Formulations and Delivery Strategies: Unleashing the Potential Against Antibiotic-Resistant Bacteria

Optimized Dosing and Delivery of Bacteriophage Therapy for Wound Infections

Antibacterial Hybrid Hydrogels

Alginate Chitosan Microbeads and Thermo-Responsive Hyaluronic Acid Hydrogel for Phage Delivery

Development of carrageenan-immobilized lytic coliphage vB_Eco2571-YU1 hydrogel for topical delivery of bacteriophages in wound dressing applications

Advances in preparation and application of antibacterial hydrogels

Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy

Injectable Phage-Loaded Microparticles Effectively Release Phages to Kill Methicillin-Resistant <i>Staphylococcus aureus</i>

Alginate- and Chitosan-Modified Gelatin Hydrogel Microbeads for Delivery of E. coli Phages

Bacteriophage Lysins: Antibacterial Effects and Medical Application

Development of phage-containing hydrogel for treating Enterococcus faecalis -infected wounds

Advanced hydrogel for management of bacterial wound infections

Bacteriophage as a potential biotherapeutics to combat present-day crisis of multi-drug resistant pathogens

The Potential Innovative Use of Bacteriophages Within the DAC® Hydrogel to Treat Patients With Knee Megaprosthesis Infection Requiring “Debridement Antibiotics and Implant Retention” and Soft Tissue Coverage as Salvage Therapy

Nano-emulsion encapsulation for the efficient delivery of bacteriophage therapeutics